La prossima frontiera in oncologia: perché la sopravvivenza deve diventare una metrica progettata, non un risultato passivo

The European tech landscape is witnessing a significant paradigm shift, particularly in the digital health sector, as artificial intelligence drives profound changes. Precision medicine, powered by AI, is revolutionizing oncology by enabling earlier diagnoses, more tailored treatments, and reduced side effects, ultimately improving patient survival rates. This technological integration marks a long-awaited transformation within the healthcare industry. At the forefront of this evolution is the concept of designing therapies that actively integrate survival principles. Healthtech innovators are developing innovative tools to achieve this, including large-scale resilience datasets that capture longitudinal biological and clinical data from exceptional survivors. AI-enabled digital twins are also emerging as a critical technology, allowing for individual simulations of disease progression and treatment responses based on unique survival potential. The impact of these advancements is far-reaching, affecting patients, healthcare providers, and innovators. By studying "exceptional survivors," researchers are unlocking new insights into human resilience, moving beyond traditional tumor genetics. Closed-loop patient feedback systems, utilizing wearables and apps, are further bridging the gap between biological and lived survival by incorporating patient-reported outcomes into adaptive treatment protocols, shifting oncology from reactive treatment to proactive survival design.